Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Prime Medicine, Inc. (PRME : NSDQ)

• Company Description    Prime Medicine Inc. is a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies. Prime Medicine Inc. is based in CAMBRIDGE, Mass. Number of Employees: 214

• Price / Volume Information    Yesterday's Closing Price: $3.81 Daily Weekly Monthly 20 Day Moving Average: 3,807,782 shares Shares Outstanding: 134.57 (millions) Market Capitalization: $512.73 (millions) Beta: 2.64 52 Week High: $6.94 52 Week Low: $1.11 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -32.92% -34.68% 12 Week 6.72% 2.30% Year To Date 30.48% 14.05%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 60 First Street - Cambridge,MA 02141 USA ph: 617-564-0013 fax: - hannah.deresiewicz@sternir.com https://primemedicine.com

• General Corporate Information    Officers Keith Gottesdiener - President; Chief Executive Officer Allan Reine - Chief Financial Officer Carman Alenson - Chief Accounting Officer Thomas Cahill - Director Wendy Chung - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 74168J101 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/27/26 Share - Related Items Shares Outstanding: 134.57 Most Recent Split Date: (:1) Beta: 2.64 Market Capitalization: $512.73 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.26 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.25 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/27/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 8.42 Price/Cash Flow: - Price / Sales: 85.78 EPS Growth vs. Year Ago Period: 27.27% vs. Previous Quarter: 21.95% Sales Growth vs. Year Ago Period: 486.12% vs. Previous Quarter: 9.87% ROE 09/30/25 - -184.47 06/30/25 - -156.16 03/31/25 - -125.05 ROA 09/30/25 - -65.44 06/30/25 - -64.41 03/31/25 - -66.33 Current Ratio 09/30/25 - - 06/30/25 - 3.56 03/31/25 - 4.78 Quick Ratio 09/30/25 - - 06/30/25 - 3.56 03/31/25 - 4.78 Operating Margin 09/30/25 - -3,301.64 06/30/25 - -4,016.83 03/31/25 - - Net Margin 09/30/25 - -3,301.64 06/30/25 - -4,016.83 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - -4,016.83 03/31/25 - -5,255.98 Book Value 09/30/25 - - 06/30/25 - 0.45 03/31/25 - 0.82 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©